Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1802 in moderate-to-severe atopic dermatitis
ChiCTR2100051917Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of telikibart in atopic dermatitis (AD) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Safety evaluation index. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
telikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2100051917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051917.